Conjugate vaccines - A breakthrough in vaccine development

Southeast Asian Journal of Tropical Medicine and Public Health

Volumn 34, Issue 2, 2003, Pages 249-253

  Mäkelä, P Helena ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE;

BACTERIAL INFECTION; BACTERIAL MEMBRANE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG USE; ENCAPSULATION; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNITY; IMMUNOLOGY; NEISSERIA MENINGITIDIS; PATHOGENESIS; REVIEW; STREPTOCOCCUS PNEUMONIAE; THAILAND; VACCINATION;

EID: 0141517685     PISSN: 01251562     EISSN: 26975718     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Anttila M, Eskola J, Åhman H, Käyhty H. Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood. Vaccine 1999;17:1970-7.
2. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19: 187-95.
3. Black S, Shinefield H, Ling S, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for preventing of pneumonia. Pediatr Infect Dis J 2002; 21: 810-15.
4. Dagan R, Melamed R, Muallem M, et al. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis 1996; 174: 1271-8.
5. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001; 344: 403-9.
6. Eskola J, Peltola H, Mäkelä PH, Käyhty H, Karanko V, Samuelson J. Antibody levels achieved in infants by course of Haemophilus influenzae type b polysaccharide/diphthteria toxoid conjugate vaccine. Lancet 1985;I:1184-1186.
7. Eskola J, Peltola H, Takala AK, et al. Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine is protective in infancy. N Engl J Med. 1987;317:717-22.
8. Galil K, Singleton R, Levine OS, et al. Reemergence of invasive Haemophilus influenzae type b disease in a well-vaccinated population in remote Alaska. J Infect Dis. 1999;179:101-6.
9. GAVI, Global Alliance for Vaccines and Immunizations, http://www.vaccinealliance.org.
10. Goldblatt D, Vaz AR, Miller E. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J Infect Dis 1998;177:1112-5.
11. Käyhty H, Peltola H, Karanko V, Mäkelä PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis. 1983;147:1100 and reply to the letter of Dr Porter Anderson, J Infect Dis 1984;149: 1034-5.
12. Käyhty H, Peltola H, Karanko V, Mäkelä PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis. 1983;147:1100 and reply to the letter of Dr Porter Anderson, J Infect Dis 1984;149: 1034-5.
13. rd International Symposium on Pneumococci and Pneumococcal Diseases. Anchorage, Alaska, 2002.
14. Kurikka S, Käyhty H, Saarinen L, Rönnberg PR, Eskola J, Mäkelä PH. Immunologic Priming by one dose of Haemophilus influenzae type b conjugate vaccine in infancy. J Infect Dis 1995;172: 1268-72.
15. Leach A, Twumasi PA, Kumah S, et al. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J Infect Dis 1997;175:200-4.
16. Leino T, Auranen K, Mäkelä PH, et al. Haemophilus influenzae type b and cross-reactive antigens in natural Hib infection dynamics; modelling in two populations. Epidemiol Infect 2002;129:73-83.
17. Levine OS, Lagos R, Munoz A, et al. Defining the burden of pneumonia in children preventable by vaccination against Haemophilus influenzae type b. Pediatr Infect Dis J 1999; 18: 1060-4.
18. Lieu T, Ray GT, Black S, et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA 2000; 283: 1460-8.
19. Mulholland K, Hilton S, Adegbola R, et al. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants. Lancet 1997; 349: 1191-7.
20. Mäkelä P, Eskola J, Käyhty H. Takala A. Vaccines against Haemophilus influenzae type b. In: Ala' Aldeen DAA, Hormaeche CE, eds. Molecular and clinical aspects of bacterial vaccine development. Chichester: John Wiley and Sons 1995: 41-91.
21. Mäkelä PH, Käyhty H. Evolution of conjugate vaccines. Expert Rev Vaccines 2002; 1: 399-410.
22. Mäkelä PH, Käyhty H, Leino T, et al. Long-term persistence of immunity after immunization with Haemophilus influenzae type b conjugate vaccine. Vaccine 2003 (in press).
23. Peltola H, Käyhty H, Sivonen A, Mäkelä PH. Haemophilus influenzae type b capsular polysaccharide vaccine in children: A double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland. Pediatrics 1977; 60: 730-7.
24. st century: Global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 2000; 13: 302-17.
25. Ramsay ME, Andrews N, Kaczmarski EB, Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 2001; 357: 195-6.
26. Robbins J, Schneerson R, Glode M, et al. Gross-reactive antigens and immunity to disease caused by encapsulated bacteria. J Allergy Clin Immunol 1975; 56: 141-51.
27. Siegrist CA. Neonatal and early life vaccinology. Vaccine 2001; 9: 3331-46.
28. Takala AK, Eskola J, Leinonen M, et al. Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with a Hib conjugate vaccine. J Infect Dis 1991; 164: 982-6.
29. Usinger WR, Lucas AH. Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides. Infect Immun 1999; 67: 2366-70.
30. Williams B, Gouws E, Boschi-Pinto C, Bryce J, Dye C. Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis 2002; 2: 25-32.